A. A. A.
syndrome is a dubious disease in the field of blood tumours, with clinical performance being complex and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
A comprehensive assessment platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment. The treatment and management of A. A.
A. syndrome requires individual development of treatment regimens, typically including drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, with timely adjustments according to disease changes. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of AAA syndrome. The platform serves China International Medical Service System, a team of domestically and abroad authoritative experts in the field of blood tumours, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.